Rethinking Alzheimer’s Treatment: It’s Time for a New Playbook in the Fight for Memory
BLOG Rethinking Alzheimer’s Treatment: It’s Time for a New Playbook in the Fight for Memory Authored by Stella Sarraf, PhDCEO, Founder In September, we recognized World Alzheimer’s Month and championed the much-needed attention and awareness to one of the greatest health crises of our time. However, the battle against Alzheimer’s is not confined to just […]
Insights from the failed Harmony Zygel Trial and hope on the horizon with Spinogenix’sSPG601
BLOG Insights from the failed Harmony Zygel Trial and hope on the horizon with Spinogenix’s SPG601 https://www.youtube.com/watch?v=_HmJMRPwFJ0 On September 24, 2025, Harmony announced that Zygel, a synthetic cannabidiol, missed the primary endpoint in its pivotal Fragile X trial. While the outcome was disappointing for many families in the Fragile X syndrome (FXS) community, it advanced […]
Restoring Synapses, Restoring Hope: A Conversation with Jerre Stead
BLOG Restoring Synapses, Restoring Hope: A Conversation with Jerre Stead (From left) Jerre Stead, Stella Sarraf, Amydis Advisory Board Member Eric Reiman, and Stead Impact Ventures CEO Tiffani Shaw) When Stead Impact Ventures Board Chair Jerre Stead sat down with Dr. Stella Sarraf, founder and CEO of Spinogenix, their discussion centered on one shared belief: […]
Honoring Dwight Clark’s Legacy: A Conversation with Steve Young
BLOG Honoring Dwight Clark’s Legacy: A Conversation with Steve Young Published September 2, 2025 At Spinogenix, stories of courage and perseverance drive our mission in developing the novel synaptic regenerative treatments to bring new hope to people living with ALS and other neurodegenerative diseases. In a recent conversation with our founder and CEO, Dr. Stella […]
Findings From First Cohort of SPG302 in Phase 2 Alzheimer Disease Trial: Sharron Gargosky, PhD
BLOG Findings From First Cohort of SPG302 in Phase 2 Alzheimer Disease Trial: Sharron Gargosky, PhD Published August 1, 2025 Thank you to NeurologyLive for featuring, Dr. Sharron Gargosky, PhD, Chief Development Officer at Spinogenix, at the AAIC2025 in Toronto Sharron highlights key findings from our Phase 2a study on SPG302, a first-in-class synaptic regenerative […]
Restoring Synapses to Fight Neurodegeneration with Spinogenix CEO Dr. Stella Sarraf — Episode 217
BLOG Restoring Synapses to Fight Neurodegeneration with Spinogenix CEO Dr. Stella Sarraf — Episode 217 Posted on: July 30, 2025 in Life Science PodcastBy: Ayesha Rashid, PhD https://www.youtube.com/watch?v=DRbPzGtzeEg In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Stella Sarraf, PhD, CEO and Founder of Spinogenix, a company pioneering novel neurodegenerative therapeutics designed […]
Spinogenix CEO and Founder Named to Forbes 50 Over 50: Innovation List
BLOG Spinogenix CEO and Founder Named to Forbes 50 Over 50: Innovation List Published Jul 30, 2025 We’re thrilled to share that our CEO and Founder, Stella Sarraf, PhD, has been named to Forbes 2025 Class of 50 Over 50: Innovation list. This recognition celebrates trailblazers who are redefining what’s possible in science, technology, and […]
This Founder Wants To Help Alzheimer’s Patients Restore Memory. Plus: Stop Spinning Your Wheels
BLOG This Founder Wants To Help Alzheimer’s Patients Restore Memory. By: Maggie McGrath, Forbes Staff andForbesWomen Team, Forbes Staff. https://youtu.be/xhAA7GL0pJU?si=XZD4CXlHpUOFRuAh Stella Sarraf founded drug discovery company Spinogenix in 2016 with a goal of finding a better way to treat neurodegenerative disorders—particularly Alzheimer’s Disease. Her approach looks at the brain’s synapses, which are the structures that allow […]
A New Era in Schizophrenia Treatment: Dr. Christoph U. Correll on the Promise of SPG302
BLOG A New Era in Schizophrenia Treatment: Dr. Christoph U. Correll on the Promise of SPG302 Spinogenix has reached a major milestone in its mission to transform neuropsychiatric care. Following FDA clearance of an IND application, enrollment is now open at a U.S. site for a Phase 2 clinical trial of SPG302—the first synaptic regenerative […]
Spinogenix Reports Positive Phase 2 Results for SPG601 in Fragile X Syndrome
BLOG Spinogenix Reports Positive Phase 2 Results for SPG601 in Fragile X Syndrome Spinogenix announced results from its Phase 2 study of SPG601, showing a strong efficacy signal in improving abnormal brain activity in Fragile X syndrome (FXS). Presented at the NIH Fragile X Centers of Excellence Conference, the study demonstrated that SPG601 significantly reduced […]